Zenas BioPharma said on Monday its experimental drug cut the risk of disease flare-ups in a late-stage study of patients with a rare immune system-related condition that can damage organs over time. ...

Key Points Dividend stocks can be a great way to generate passive income. Investors must ensure that companies are generating sufficient free cash flow and earnings to cover their dividends, ideally with the intention of raising them in the future. Ford's trailing-12-month dividend yield is around 4.5%, while Pfizer's is around 6.9%. 10 stocks we like better than Ford Motor Company › Dividend stocks can be a good strategy for investors seeking a reliable and potentially more predictable stream o ...

Britain's medicines regulator said on Monday it was reviewing Novo Nordisk's application for an oral 25 milligram version of its weight-loss drug Wegovy and anticipated making a decision before the end of the year. ...

Core Viewpoint - LifeMD, Inc. has expanded its virtual weight management offerings by introducing Novo Nordisk's Wegovy pill, the first FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health, available for eligible patients at a starting price of $149 per month [1][5]. Group 1: Product Offering - LifeMD is now offering Wegovy (semaglutide) through its telehealth platform, enhancing access to affordable branded treatment options for weight management [1]. - Wegovy is indicated for reducing excess body weight, supporting long-term weight maintenance, and lowering the risk of major adverse cardiovascular events, with a Phase 3 trial showing a mean weight loss of 16.6% compared to 2.7% with placebo [3]. - The oral formulation of Wegovy is expected to attract patients who are hesitant to use injectable treatments, thereby broadening access to GLP-1 therapies [3]. Group 2: Collaboration and Integration - LifeMD's collaboration with Novo Nordisk is highlighted, with LifeMD being featured as a trusted telehealth provider on NovoCare and Wegovy websites, reflecting the demand for convenient access to GLP-1 therapies [2]. - The integration with NovoCare Pharmacy allows streamlined access to both injectable and oral GLP-1 medications, including Wegovy and Ozempic, at competitive cash-pay pricing [4]. - LifeMD provides a comprehensive experience that includes virtual visits, ongoing clinical oversight, diagnostic testing, pharmacy fulfillment, and simplified billing [4]. Group 3: Pricing and Availability - Wegovy 1.5mg and 4mg pills are available for $149 per month, with future pricing adjustments planned for April 15, 2026, where 4mg will be priced at $199 and higher doses at $299 per month [5].

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is now available at a cash price of $149 per month at more than 70,000 pharmacies nationwide via GoodRx. For consumers looking to easily evaluate their options for both treatment and access to the medication, they will soon be able to connect with a licensed healthcare provider through GoodRx for Weight. ...

Core Insights - Weight Watchers has launched the Med+ program, integrating Novo Nordisk's newly FDA-approved oral formulation of Wegovy, enhancing access to GLP-1 treatments and reinforcing its leadership in comprehensive weight management care [1][4] Group 1: Integrated Care Model - Weight Watchers is recognized as a NovoCare provider, delivering FDA-approved GLP-1 medications alongside expert clinical care through its Med+ and GLP-1 Success Program [2] - The integrated care model combines access to board-certified physicians, evidence-based behavioral science, coaching, community support, and digital tools, leading to better real-world outcomes [2][5] - Members engaging with the GLP-1 Success Program lost 61.3% more body weight at one month and 29.1% more at twelve months compared to those not engaged in the program [4] Group 2: Leadership and Innovation - CEO Tara Comonte emphasized that the next era of weight health focuses on helping individuals succeed with medication, highlighting the importance of support in achieving results [3] - The introduction of the Wegovy pill offers a once-daily option, appealing to individuals hesitant about injectable therapies, with access starting at $149 per month [4] - Weight Watchers aims to expand access to GLP-1 treatments while ensuring patients receive necessary support beyond prescriptions [4][5] Group 3: Company Background - Weight Watchers has over 60 years of experience in science-backed weight management, being the most studied commercial weight management program globally [6][7] - The company provides a holistic approach that includes clinical interventions and access to GLP-1 medications when appropriate, supported by a global network of coaches and community [7] - Weight Watchers offers solutions directly to members and through its platform for employers, health plans, and payers, focusing on personalized support [7]

Core Insights - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting for the commercialization of VIZZ in the Middle East, which includes revenue sharing and milestone payments [1][2][3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved eye drop for presbyopia, impacting approximately 1.8 billion people globally and 128 million in the U.S. [9] - Lunatus is a Dubai-based pharmaceutical company specializing in the commercialization of healthcare products in the Middle East, established in 2003 [10] Product Information - VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing aceclidine as the active ingredient [5] - The product is preservative-free and provided in single-dose vials, offering a pupil-selective miotic effect to improve vision [5] Market Context - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, aimed at expanding access to presbyopia treatment in key strategic regions [3] - Presbyopia affects nearly all individuals over the age of 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [4]

®2®3 PLAINSBORO, N.J.and BAGSVÆRD, Denmark, Jan. 5, 2026 /PRNewswire/ -- Wegovy pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity. Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-rel ...

Core Insights - Crinetics Pharmaceuticals reported unaudited and preliminary net product revenue of over $5 million for PALSONIFY in the fourth quarter of 2025, with over 200 enrollment forms submitted by the end of December [2][4][5] - Positive topline results from the fourth cohort of the Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant were announced, showing a 67% mean reduction in androstenedione levels and enabling 88% of participants to successfully reduce glucocorticoid doses to physiological levels [1][8][9] Company Performance - The launch of PALSONIFY, approved by the FDA on September 25, 2025, has been characterized by strong execution, with over 200 enrollment forms and a broad prescriber base [3][4][7] - Feedback from patients, physicians, and payers has been positive, leading to early formulary inclusions by payers [4][5] Clinical Study Results - The fourth cohort of the Phase 2 TouCAHn trial involved 10 patients with classic CAH, with treatment resulting in significant reductions in androstenedione levels [5][8] - Atumelnant was well-tolerated, with no serious adverse events reported, and a favorable benefit/risk profile maintained throughout the study [11][14] Future Outlook - Crinetics plans to host an investor conference call to discuss the topline results from the study, indicating ongoing engagement with investors and stakeholders [15][16] - Atumelnant is positioned as a potential transformational treatment for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with ongoing Phase 3 clinical development [17][20]

Core Viewpoint - Novo Nordisk has launched the first-ever GLP-1 oral pill for weight loss in the U.S., marking a significant advancement in obesity treatment [1][2]. Pricing and Accessibility - The cash prices for the Wegovy pill range from $149 to $299 per month, depending on the dosage, which aims to address affordability issues associated with existing weekly injection treatments [2][4]. - The starting dose of 1.5 milligrams is available at over 70,000 U.S. pharmacies and select telehealth providers, with higher doses expected to be available shortly [3]. - Patients with insurance can access the drug for as low as $25 per month, while cash-paying patients can also purchase it through a deal with TrumpRx for $149 per month [4][5]. Market Potential - The GLP-1 market is projected to be worth approximately $100 billion by the 2030s, with oral drugs potentially capturing a 24% market share, equating to around $22 billion [7]. - Novo Nordisk's launch gives it a competitive edge as it awaits FDA approval for a rival pill from Eli Lilly later this year [8]. Clinical Efficacy - In a phase three trial, the highest dose of the oral semaglutide led to an average weight loss of 16.6% after 64 weeks, with a 13.6% weight loss observed across all participants [11]. - The Wegovy pill is reported to be slightly more effective than Eli Lilly's experimental oral drug, which does not impose dietary restrictions [12]. Regulatory Approval - The FDA approved the Wegovy pill for weight loss and for reducing the risk of major cardiovascular events in adults with obesity and established cardiovascular disease [8][9].